logo-loader
viewSynairgen PLC

Synairgen completes hospital recruitment for coronavirus trial

Synairgen said a successful outcome for the trial would provide valuable information for the continued development of SNG001, an inhaled formulation of interferon-beta-1a, or coronavirus patients

Synairgen PLC -

Synairgen PLC (LON:SNG), the respiratory drug discovery and development company, said it has completed recruitment of hospitalised patients with coronavirus (COVID-19) for its clinical trial of SNG001.

Synairgen's clinical trial in COVID-19 patients (SG016) is a double-blind, placebo-controlled trial. The 220 patient trial comprises 100 patients initiated in hospitals and 120 patients initiated in the home setting.

The patients participating in the hospital setting have been recruited across a number of National Health Service (NHS) trusts. The trial has been adopted by the NIHR Respiratory Translational Research Collaboration, a union of leading centres in respiratory medicine in the UK.

Synairgen said a successful outcome for the trial would provide valuable information for the continued development of SNG001, an inhaled formulation of interferon-beta-1a, in COVID-19 patients.

Results from the hospital setting are expected in July 2020, as previously announced.

“A successful outcome from this trial could be a critical step towards strengthening the fight against the COVID-19 pandemic,” said Richard Marsden, the chief executive officer of Synairgen in a statement.

Shares in Synairgen, which started the year trading at around 5.94p, eased 0.7% to 45.7p in early deals.

Quick facts: Synairgen PLC

Price: 37.5 GBX

AIM:SNG
Market: AIM
Market Cap: £56.04 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen PLC pleased with further positive data from lead COPD drug

Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...

on 28/6/18

2 min read